Phase II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small-cell lung cancer

@article{Okamoto2000PhaseIS,
  title={Phase II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small-cell lung cancer},
  author={Hiroaki Okamoto and Koshiro Watanabe and Yoshihiko Segawa and Yukito Ichinose and Akira Yokoyama and Shuichi Yoneda and Hisanobu Niitani},
  journal={International Journal of Clinical Oncology},
  year={2000},
  volume={5},
  pages={316-322}
}
Background. This phase II study was designed to determine the toxicity and efficacy of a low dose of docetaxel plus a standard dose of cisplatin for patients with metastatic non-small-cell lung cancer (NSCLC). Methods. Eligibility criteria included metastatic disease (stage IV) of NSCLC and a performance status (PS) of 0-2. Cisplatin 80 mg/m2 was given i.v. on day 1 and docetaxel 60 mg/m2 was given i.v. on day 1. Treatment was repeated every 3 to 4 weeks. Results. Forty-five patients were… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1998
View 5 Excerpts
Highly Influenced

First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.

Annals of oncology : official journal of the European Society for Medical Oncology • 1998
View 2 Excerpts

Phase III study of cisplatin (C) with or without gemicitabine (G) in patients with advanced nonsmall cell lung cancer (NSCLC) (abstract 1747)

A Sandler, J Nemunaitis, C Dehnam
Proc Am Soc Clin Oncol • 1998

Docetaxel and cisplatin combination in patients with non-small cell lung cancer (NSCLC): a multicenter phase II trial (abstract 37)

CP Belani, P Bonomi, T Dobbs
Lung Cancer • 1997

Phase I/II study of docetaxel (TXT) and cisplatin (CDDP) in patients with previously untreated metastatic non-small cell lung cancer (NSCLC) (abstract 30)

A Karato, I Hayashi, Y Segawa
Lung Cancer • 1997
View 2 Excerpts

Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1996
View 1 Excerpt

Phase II study of a 75 - mg / m 2 dose of docetaxel with prednisone premedication for patients with advanced non - small cell lung

J Zalcberg, M Millward, J Bishop
cancer • 1995